Related Experiment Video
Updated: Aug 5, 2026
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Expression of PCAT19, miR-195, ITGA6, and E-cadherin in prostate cancer: a preliminary tissue-based study
Samia Hussein1, Mansour Zahra2, Amr A Shalaby2
1Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Zagazig University, Egypt.
Background:
Prostate cancer (PC) is the second most common solid cancer affecting men. LncRNA PCAT19 has a carcinogenic role in multiple solid and hematological cancers. Additionally, miR-195 was significantly downregulated in multiple malignancies. Moreover, ITGA6 promotes pathways that control carcinogenesis. E-cadherin is a glycoprotein involved in epithelial cell adhesion and maintaining tissue integrity. E-cadherin loss is related to epithelial-mesenchymal transition (EMT) and cancer metastasis. This preliminary study investigated the expression of PCAT19, miR-195, ITGA6, and E-cadherin in PC tissues.
Subjects & Methods:
Seventy-two tissue specimens from 36 PC patients were enrolled in this study. The diseased group included 36 primary PC tissues, and the control group included 36 specimens from their non-neoplastic adjacent tissues. Gene expression of LncRNA PCAT19, miR-195, and ITGA6 in tissues was estimated by Reverse transcription- quantitative polymerase chain reaction (RT-qPCR), and E-cadherin expression was detected by immunohistochemistry.
Results:
A statistically significant upregulation inPCAT19 (7.92-fold) and ITGA6 (6.67-fold) gene expression and downregulation of miR-195 (4.17-fold) gene expression in tumor tissues compared to adjacent non-neoplastic tissues were recorded. During follow-up, 11 of 36 patients (30.6%) died, and disease progression occurred in 6 of 25 evaluable patients (24.0%). There was a statistically significant decrease in PCAT19 and ITGA6 and an increase in miR-195 among surviving cases compared with dead cases. Receiver operating characteristic (ROC) curve analysis revealed that PCAT19 at a cutoff of > 8.89-fold demonstrated promising discriminatory performance for advanced-stage PC, with an area under the curve (AUC) of 0.84 (95% confidence interval (CI): 0.69-0.99, P < 0.001), 70% sensitivity, 93.7% specificity, 93.3% positive predictive value, 71.4% negative predictive value, and an overall diagnostic accuracy of 80.6%. In comparison, ITGA6 (AUC = 0.73) and miR-195 (AUC = 0.71) exhibited only fair discriminatory ability.
Conclusion:
Upregulation of PCAT19 and ITGA6, and downregulation of miR-195, in prostate cancer tissues may be associated with disease aggressiveness.
